0001209191-21-062653.txt : 20211103
0001209191-21-062653.hdr.sgml : 20211103
20211103153012
ACCESSION NUMBER: 0001209191-21-062653
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211029
FILED AS OF DATE: 20211103
DATE AS OF CHANGE: 20211103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Willoughby Scott B.
CENTRAL INDEX KEY: 0001877368
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 211375075
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-10-29
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001877368
Willoughby Scott B.
C/O SANGAMO THERAPEUTICS, INC.
7000 MARINA BLVD
BRISBANE
CA
94005
0
1
0
0
SVP, Gen. Counsel & Secretary
Common Stock
2021-10-29
4
F
0
140
8.12
D
54455
D
Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on October 29, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on October 29, 2021 of $8.12/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").
Includes: (a) 265 shares of common stock resulting from the October 29, 2021 vesting of the Reporting Person's November 10, 2020 RSU grant and 405 shares of common stock subject to such RSU grant that will vest in one remaining installment on April 29, 2022; (b) 23,001 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on April 24, 2020 that will vest in two remaining annual installments on April 24, 2022 and 2023 respectively; (continued in Footnote 3)
Continued from Footnote 2 - (c) 13,750 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021; and (d) 7,500 shares of common stock subject to RSUs granted to the Reporting Person on August 1, 2021. All such RSUs vest with respect to 1/3rd of the shares granted in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended), through such dates and subject to acceleration as provided in the 2018 EIP, as amended.
/s/ Matthew Colvin, Attorney-in-Fact for Scott B. Willoughby
2021-11-02